DVM
TEVA icon

Dreman Value Management’s Teva Pharmaceuticals TEVA Stock Holding History

Dreman Value Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$3K Hold
161
– – ﹤0.01% 451
2017
Q4 		$3K Sell
161
-41,887
-100% -$630K ﹤0.01% 443
2017
Q3 		$740K Sell
42,048
-2,390
-5% -$53.8K 0.41% 82
2017
Q2 		$1.48M Buy
44,438
+28,792
+184% +$891K 0.81% 33
2017
Q1 		$502K Sell
15,646
-1,105
-7% -$37.7K 0.29% 121
2016
Q4 		$607K Sell
16,751
-15,218
-48% -$608K 0.34% 78
2016
Q3 		$1.47M Sell
31,969
-1,305
-4% -$68.1K 0.89% 34
2016
Q2 		$1.67M Sell
33,274
-709
-2% -$37.7K 1.03% 30
2016
Q1 		$1.82M Buy
+33,983
New +$1.99M 0.21% 134
2015
Q4 		– Sell
-42,892
Closed -$2.42M – 389
2015
Q3 		$2.42M Sell
42,892
-47,453
-53% -$3.08M 0.24% 115
2015
Q2 		$5.34M Sell
90,345
-9,788
-10% -$604K 0.44% 79
2015
Q1 		$6.24M Sell
100,133
-19,705
-16% -$1.15M 0.54% 66
2014
Q4 		$6.89M Sell
119,838
-37,611
-24% -$2.1M 0.57% 56
2014
Q3 		$8.46M Sell
157,449
-1,641
-1% -$86.9K 0.69% 36
2014
Q2 		$8.34M Sell
159,090
-24,233
-13% -$1.24M 0.63% 49
2014
Q1 		$9.69M Buy
183,323
+35,995
+24% +$1.66M 0.75% 28
2013
Q4 		$9.03M Sell
147,328
-17,636
-11% -$694K 0.68% 36
2013
Q3 		$6.23M Buy
+164,964
New +$6.44M 0.56% 90

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dreman Value Management's TEVA Position: Q1 2018 in Review

Dreman Value Management held its Teva Pharmaceuticals (TEVA) position steady in Q1 2018 at 161 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #451.

Dreman Value Management first reported a position in TEVA in Q3 2013 and has held it in 18 quarters since. The position peaked at $9.69M in Q1 2014. 506 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

  • Dreman Value Management held 161 shares of Teva Pharmaceuticals worth $3K as of Q1 2018.
  • Dreman Value Management left its Teva Pharmaceuticals share count unchanged in Q1 2018.
  • Teva Pharmaceuticals made up ﹤0.01% of Dreman Value Management's portfolio in Q1 2018, its #451 holding.
  • Dreman Value Management first reported a position in Teva Pharmaceuticals in Q3 2013 and has held it in 18 quarters since.
  • Dreman Value Management's Teva Pharmaceuticals position peaked at $9.69M in Q1 2014.
  • 506 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2018.

Based on Dreman Value Management's 13F filing for Q1 2018, filed 2 May 2018.